February 11, 2014
January 28, 2014
Dr. Arnaud Foussat at Immunotherapy Forum
Cellular Immunotherapy of chronic inflammation and autoimmunity using autologous antigen-specific T regulatory (Treg) cells
January 15, 2014
January 7, 2014
Treg: Regulatory T Cells and T Helper Cells
We are focusing on chronic inflammatory diseases where current treatments show limited efficacy, limited tolerability and for which many of the patients treated develop resistance.
Ovasave® is our lead product candidate. The first in man, open label, phase I/II clinical trial for severe refractory Crohn's Disease patients has been successfully completed (link1) (link2) and showed good tolerability and a strong efficacy signal in the best dose group. A phase IIb placebo controlled study is planned in the same patient population.
More information on Crohn's disease here
Col-Treg is our second product candidate in development for Autoimmune Uveitis, a rare disease with very limited treatment options. The next step in this program will be a phase I/II proof of principle clinical trial.
More information on Autoimmune Uveitis here
Other product candidates targeting the central nervous system antigen (myelin) and the ubiquitous Heat Shock Protein antigen (HSP60) are in early stages of development.